Non disponible en dehors du Royaume-Uni et de l'Irlande
Application
Camostat mesylate has been used to determine the effect of transmembrane protease, serine (TMPRSS) family proteases on cell-cell fusion.
Camostat mesylate may be used in cell signaling studies.
Biochem/physiol Actions
Camostat mesylate (CM) is used to treat pancreatitis and reflux esophagitis after gastrectomy.
Camostat mesylate inhibits the production of TNF-α and monocyte chemoattractant protein-1 (MCP-1) by monocytes. It also inhibits the activity of pancreatic stellate cells. Camostat mesylate regulates the cytokine expression and inflammation and is effective in the treatment of dibutyltin dichloride-induced rat pancreatic fibrosis.
Camostat is a synthetic, orally bioavailble serine protease inhibitor and airway epithelial sodium channel (ENaC) attenuator.
Features and Benefits
This compound is featured on the Acid-Sensing (Proton-gated) Ion Channels (ASICs) page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Novartis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
Packaging
10, 50 mg in glass bottle
Ce produit répond aux critères suivants pour être admissible aux récompenses suivantes :